Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

This male cancer can be easily screened for, but the lack of symptoms in the early stages makes it easy to overlook.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.